# Aktis Oncology, Inc.: overview

AKTS · Nasdaq · CIK 2035832 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/akts.md) · [Financials](/companies/akts/financials.md) · [Filings](/companies/akts/filings.md) · [Insiders](/companies/akts/insiders.md)

Latest reported revenue: [$3.4m](/filings/0001193125-26-349144.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-349144).

## Last eight quarters

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.4](/filings/0001193125-26-216749.md) | [1.6](/filings/0001193125-26-349144.md) | [3.2](/filings/0001193125-26-216749.md) | [3.4](/filings/0001193125-26-349144.md) |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | [(1253.8%)](/filings/0001193125-26-216749.md) | [(1309.4%)](/filings/0001193125-26-349144.md) | [(703.6%)](/filings/0001193125-26-216749.md) | [(854.0%)](/filings/0001193125-26-349144.md) |
| Net margin | % | [(1035.6%)](/filings/0001193125-26-349144.md) | [(1129.0%)](/filings/0001193125-26-349144.md) | [(567.9%)](/filings/0001193125-26-349144.md) | [(713.5%)](/filings/0001193125-26-349144.md) |
| Diluted EPS | $ per share | [(18.60)](/filings/0001193125-26-216749.md) | [(22.39)](/filings/0001193125-26-349144.md) | [(0.38)](/filings/0001193125-26-216749.md) | [(0.44)](/filings/0001193125-26-349144.md) |
| Free cash flow | $m | [(19.4)](/filings/0001193125-26-216749.md) | [(17.7) d](/filings/0001193125-26-349144.md) | [(26.1)](/filings/0001193125-26-216749.md) | [(21.8) d](/filings/0001193125-26-349144.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure.

## Last five fiscal years

Not reported.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/akts/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [MPM BIOIMPACT LLC](/funds/1687078.md) | 2026-06-30 | $155.9m | 4,835,872 |  | Unchanged |
| [EcoR1 Capital, LLC](/funds/1587114.md) | 2026-06-30 | $155.5m | 4,824,469 |  | Unchanged |
| [Blue Owl Capital Holdings LP](/funds/1858703.md) | 2026-06-30 | $99.0m | 3,070,219 |  | Reduced −91,129 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $73.4m | 2,278,358 |  | Added +166,231 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $63.4m | 1,966,244 |  | Reduced −350,800 |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $51.3m | 1,592,043 |  | Unchanged |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $42.4m | 1,314,405 |  | Reduced −188,679 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $42.4m | 1,314,267 |  | Not compared |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $32.1m | 996,351 |  | Unchanged |
| [Octagon Capital Advisors LP](/funds/1839435.md) | 2026-06-30 | $31.0m | 960,847 |  | Unchanged |

## Recent filings

[All 60 filings](/companies/akts/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-13 | 16:05 ET | [10-Q](/filings/0001193125-26-349144.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349144 |
| 2026-08-13 | 16:04 ET | [8-K](/filings/0001193125-26-349133.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349133 |
| 2026-05-11 | 16:06 ET | [10-Q](/filings/0001193125-26-216749.md) | Quarterly report, period 2026-03-31 | 0001193125-26-216749 |
| 2026-05-11 | 16:04 ET | [8-K](/filings/0001193125-26-216716.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-216716 |
| 2026-04-16 | 16:01 ET | [8-K](/filings/0001193125-26-158944.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-158944 |
| 2026-03-30 | 18:47 ET | [8-K](/filings/0001193125-26-132524.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-132524 |
| 2026-03-30 | 17:29 ET | [10-K](/filings/0001193125-26-131748.md) | Annual report, period 2025-12-31 | 0001193125-26-131748 |
| 2026-01-20 | 17:44 ET | [SCHEDULE 13D](/filings/0001231919-26-000070.md) | Ownership report, active investor | 0001231919-26-000070 |
| 2026-01-20 | 14:01 ET | [SCHEDULE 13D](/filings/0000935836-26-000046.md) | Ownership report, active investor | 0000935836-26-000046 |
| 2026-01-14 | 16:58 ET | [SCHEDULE 13D](/filings/0001193125-26-013015.md) | Ownership report, active investor | 0001193125-26-013015 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-131748.md), filed Mar 30, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d800db0d-3760-4803-8c9d-8b4480b7a9c3)

## About the filer

- CIK: 2035832
- Tickers: AKTS
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.